

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

) Atty Docket No.: 0075.00

DEC 1 2 2002 TECH CENTER 1600/2900

Group Art Unit: 1646

Examiner: Unassigned

Application No. 10/032,238

Filed: 12/21/2001

Title: STORAGE STABLE POWDER

In re the application of: Jayne Hastedt et al.

COMPOSITIONS OF INTERLEUKIN-4

RECEPTOR

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on December 5, 2002

Signed: Muna Catte

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents Washington, DC 20231

Dear Sir:

The references listed in the attached Form PTO/SB/08A,B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

Copies of the references are enclosed, as required under 37 CFR §§1.98.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

| the date of en | nonths of the filing date of a national application; within three months of try of the national stage as set forth in section 1.491 in an international r before the mailing date of a first Office action on the merits (whichever ast); |
|-------------------------------|--|
| of a first Officunder section | ee months from the filing date of an application and after the mailing date ce action on the merits, but before the mailing date of either a final action 1.113 or a notice of allowance under section 1.311 (whichever occurs eccompanied by: the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00); or one of the following statements as specified in 37 CFR 1.97(e) that: each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement; or |
| | ing date of either a final action under section 1.113 or a notice of der section 1.311, but on or before the payment of the issue fee, and is by each of: the following petition: Applicant hereby requests consideration of the accompanying information disclosure statement; the petition fee set forth in 37 CFR 1.17(i) (\$130.00); and one of the following statements as specified in 37 CFR 1.97(e) that: each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure |

statement; or

no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement. Attached is Check No. _ in the amount of \$0. Please charge the amount of \$___ to Deposit Account 500348 If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 50-0348. Respectfully submitted, INHALE THERAPEUTIC SYSTEMS, INC. Dated: December 5, 2002 Reg. No. 43,275 San Carlos, CA 94070 (650) 631-3100

DEC 1 0 2002

PTO/SB/08A (10-01) Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/032,238 INFORMATION DISCLOSURE DEC 1-21 2002 Filing Date 12/21/2001 STATEMENT BY APPLICANT **First Named Inventor** Javne Hastedt Art Unit 1646 TECH CENTER 1600/2900 (use as many sheets as necessary) Examiner Name Unassigned Attorney Docket Number 0075.00 Sheet of

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|----------|---|--------------------------------|--|---|
| Examiner Initials* | | Document Number Number - Kind Code 2 (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | AB | US- 5,599,905 | 02/04/1997 | B. Mosley et al. | - Series Aspect |
| | | US- | | | |
| | | US- | | | |
| | <u> </u> | US- | | | |
| | | US- | | | |
| | <u> </u> | US- | | | |
| | | US- | | | |
| | <u> </u> | US- | | | |
| | | US- | | | |
| | L | US- | | | |
| | L_ | US- | | | |
| | | US- | | | |

| | FOREIGN PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|----------|
| Examiner Initials* | Cite No.1 | Foreign Patent Document Country Code3 -Number ⁴ -Kind Code ⁵ (il known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T6 |
| | AC | WO 0108708 | 02/08/2001 | Case West. Res. U. | | |
| | AD | WO 0162272 | 08/30/2001 | Immunex | | |
| | <u> </u> | | | | | |
| | | | * | | | |
| | - | | | | | Н |
| | | | | | | \vdash |
| | | | | | | \vdash |
| | | | | | | |
| | | <u> </u> | | | | |

| , | | | |
|-----------|---|------------|---|
| Examiner | | Date | |
| Signature | · | Considered | 1 |
| | | | |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

onnominate and not considered. Include copy of his form with next communication to applicants.

1 Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Office the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

2

Sheet

(use as many sheets as necessary)

of

Complete if Known 10/032,238 **Application Number** 12/21/2001 Filing Date First Named Inventor Javne Hastedt Group Art Unit 1646 Unassigned Examiner Name Attorney Docket Number 0075.00

| Examiner | Cite | OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue | T ² |
|----------|------|--|----------------|
| nitials* | No.1 | number(s), publisher, city and/or country where published. | ╁╴ |
| | | | Į |
| | AA | ROBERT LANGE, "Interleukin 4 Receptor Immunex Corp.," Database CA 'Onlinet Chem. Abstract Serv., Columbus, Ohio, US; retrieved from STN Database accession no. 132-220921 CA XP002216866, Current Opinion in Cardiovalscular, Pulmonary & Renal Investigational Drug 1999, 1(4), p. 526-531, abstract. | - |
| | | | ļ |
| | | | |
| | T | | |
| | | | 1 |
| | - | | T |
| | 1 | | |
| | - | | 十 |
| | | | |
| | - | | + |
| | | | |
| | | | - |
| | | | |
| • | | | |
| | Т | | - |
| | | | |
| | +- | | 丁 |
| | . | | |
| | ╀ | | 十 |
| | | | İ |
| | | | |
| | | | \perp |
| | T | | |
| | | | |
| | 1 | | |

| 1 | Examiner | Date |
|---|-----------|------------|
| | Signature | Considered |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.